GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Operating Margin %

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Provectus Biopharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-0.63 Mil. Provectus Biopharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Provectus Biopharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Provectus Biopharmaceuticals's Operating Margin % or its related term are showing as below:


PVCT's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -168.78
* Ranked among companies with meaningful Operating Margin % only.

Provectus Biopharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Provectus Biopharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-0.63 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.91 Mil.

Warning Sign:

Provectus Biopharmaceuticals Inc has never been profitable in the past 3 years. It lost money every year.


Provectus Biopharmaceuticals Operating Margin % Historical Data

The historical data trend for Provectus Biopharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Operating Margin % Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Provectus Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Provectus Biopharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Operating Margin % falls into.



Provectus Biopharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Provectus Biopharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-2.91 / 0
= %

Provectus Biopharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0.629 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provectus Biopharmaceuticals  (OTCPK:PVCT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Provectus Biopharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932
Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.
Executives
Jeffrey Allen Morris 10 percent owner 1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines officer: Chief Financial Officer 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing director 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass officer: See Remarks 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper officer: Interim CEO, CFO, COO 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter director, officer: Chief Technology Officer PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv director 191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams 10 percent owner 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott director, 10 percent owner, officer: President PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Headlines

From GuruFocus

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

By Stock market mentor Stock market mentor 01-09-2023